Two-way ANOVA showed a main effect of postnatal HFD treatment (p < 0.05), indicating an increase in the level of pIRS1 (i.e., decreased IRS-1 downstream signaling), but not for maternal HFD/obesity in pIRS1 levels. The gene discussed is IRS1; the disease is obesity due to melanocortin 4 receptor deficiency.